Blastomycosis, unspecified
ICD-10 B40.9 is a billable code used to indicate a diagnosis of blastomycosis, unspecified.
Blastomycosis is a systemic fungal infection caused by the dimorphic fungus Blastomyces dermatitidis, primarily affecting the lungs but can disseminate to other organs. The infection is endemic in certain regions of North America, particularly around the Great Lakes and the Ohio and Mississippi River valleys. Patients may present with a variety of symptoms, including cough, fever, night sweats, and weight loss. In severe cases, it can lead to pneumonia or disseminated disease affecting the skin, bones, and central nervous system. Diagnosis is typically made through clinical evaluation, imaging studies, and laboratory tests, including culture and histopathological examination. Treatment usually involves antifungal medications such as itraconazole or amphotericin B, especially in immunocompromised patients who are at higher risk for severe disease. The unspecified nature of this code indicates that the specific site of infection or severity is not documented, which can complicate treatment decisions and patient management.
Detailed clinical notes on symptoms, diagnostic tests, and treatment plans.
Patients presenting with respiratory symptoms and a history of exposure in endemic areas.
Consideration of immunocompromised status and potential for disseminated disease.
Pulmonary function tests, imaging studies, and treatment response documentation.
Patients with chronic cough and pulmonary nodules on imaging.
Differentiation from other pulmonary infections and conditions.
Used when a fungal infection is suspected and cultures are taken.
Document the reason for the culture and any relevant clinical findings.
Infectious disease specialists may require additional documentation on treatment response.
Common symptoms include cough, fever, night sweats, and weight loss. In severe cases, it can lead to pneumonia or disseminated disease.
Diagnosis is made through clinical evaluation, imaging studies, and laboratory tests, including culture and histopathological examination.
Antifungal treatments include itraconazole for mild to moderate cases and amphotericin B for severe cases or in immunocompromised patients.
